Edesa Biotech (EDSA) director granted 19,000 restricted share units

Rhea-AI Filing Summary

Sistilli Carlo reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. director Carlo Sistilli reported an equity grant. He received 19,000 restricted share units of Common Shares at a price of $0.00 per share under the company’s 2019 Equity Incentive Compensation Plan. These units vest in equal portions over twelve months starting on the grant date.

Following this award, Sistilli directly holds 49,417 Common Shares. Separately, 522 Common Shares are held indirectly through York-Cav Enterprises, Inc., which he partially owns and for which he disclaims beneficial ownership beyond his pecuniary interest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sistilli Carlo

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	19,000	$0.00	--
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 49,417 shares (Direct, null); Common Shares — 522 shares (Indirect, Held by York-Cav Enterprises, Inc.)

Footnotes (1)

1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. York-Cav Enterprises, Inc. is partially owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Key Figures

Restricted share units granted: 19,000 shares Grant price per share: $0.00 per share Direct holdings after grant: 49,417 shares +3 more

6 metrics

Restricted share units granted 19,000 shares Equity grant of Common Shares under 2019 plan

Grant price per share $0.00 per share Restricted share unit award compensation value

Direct holdings after grant 49,417 shares Common Shares directly owned by Carlo Sistilli

Indirect holdings via York-Cav 522 shares Common Shares held by York-Cav Enterprises, Inc.

Vesting period 12 months Restricted share units vest monthly from grant date

Award plan 2019 Equity Incentive Compensation Plan Plan under which restricted share units were granted

Key Terms

restricted share units, 2019 Equity Incentive Compensation Plan, pecuniary interest, beneficial ownership, +1 more

5 terms

restricted share units financial

"Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Equity Incentive Compensation Plan financial

"issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions"

pecuniary interest financial

"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"

beneficial ownership regulatory

"shall not be deemed an admission of beneficial ownership of all of the reported shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Section 16 regulatory

"for purposes of Section 16 or for any other purpose"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sistilli Carlo

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM L3R 5H6

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	05/27/2026		A		19,000(1)	A	$0(1)	49,417	D
Common Shares								522	I	Held by York-Cav Enterprises, Inc.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

2. York-Cav Enterprises, Inc. is partially owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Peter J. Weiler, Attorney-in-Fact for Carlo Sistilli	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Edesa Biotech (EDSA) director Carlo Sistilli report on this Form 4?

He reported receiving 19,000 restricted share units of Common Shares as an equity award. The grant is compensation, not an open-market purchase, and was made under Edesa Biotech’s 2019 Equity Incentive Compensation Plan with a stated price of $0.00 per share.

How do the 19,000 restricted share units for EDSA vest over time?

The 19,000 restricted share units vest in equal proportions over twelve months, starting on the grant date. This means a portion of the award becomes fully owned each month, aligning compensation with ongoing service over the one-year vesting period.

How many Edesa Biotech (EDSA) shares does Carlo Sistilli hold after this grant?

After the grant, Carlo Sistilli directly holds 49,417 Common Shares of Edesa Biotech. In addition, 522 Common Shares are reported as indirectly held through York-Cav Enterprises, Inc., a company he partially owns, with beneficial ownership limited to his pecuniary interest.

What is York-Cav Enterprises, Inc.’s role in Carlo Sistilli’s EDSA holdings?

York-Cav Enterprises, Inc. holds 522 Common Shares reported as indirect holdings for Carlo Sistilli. He is a partial owner of York-Cav and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, according to the disclosure language.

Is the 19,000-share EDSA award a market transaction or compensation?

The 19,000-share award is compensation, not a market trade. It is described as a grant of restricted share units issued under Edesa Biotech’s 2019 Equity Incentive Compensation Plan, with a transaction price per share of $0.00, reflecting an equity incentive rather than a purchase.